

**VICPLAS INTERNATIONAL LTD
AND ITS SUBSIDIARIES**
(Registration No. 199805362R)

**CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED**

31 JANUARY 2025

C O N T E N T S

	<u>PAGE</u>
Condensed interim consolidated statement of profit or loss and other comprehensive income	3
Condensed interim statements of financial position	4
Condensed interim statements of changes in equity	5
Condensed interim consolidated statement of cash flows	7
Notes to the condensed interim consolidated financial statements	9
Other information required by Listing Rule Appendix 7.2	18

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

A. CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
Period ended 31 January 2025

		Group		
		S\$'000		%
		6 months ended 31 January 2025	6 months ended 31 January 2024	Increase/ (Decrease)
	Note			
Revenue		54,309	51,057	6.4
Other income		2,545	2,963	(14.1)
Changes in inventories of finished goods and work-in-progress		3,185	2,426	31.3
Raw materials and consumables used		(27,428)	(26,447)	3.7
Purchase of finished goods for resale		(1,414)	(1,006)	40.6
Employee benefits expense		(18,176)	(17,711)	2.6
Depreciation and amortisation expenses		(3,485)	(3,420)	1.9
Other operating expenses		(8,364)	(7,173)	16.6
Finance costs		(667)	(412)	61.9
Profit before tax	5	505	277	82.3
Income tax expense	6	(260)	(53)	390.6
Profit after tax		245	224	9.4
Other comprehensive income, net of tax:				
<i>Items that may be reclassified subsequently to profit or loss:</i>				
Exchange differences on translation of foreign operations		8	132	(93.9)
Other comprehensive income, net of tax		8	132	(93.9)
Total comprehensive income		253	356	(28.9)
Profit attributable to:				
Owners of the Company		245	224	9.4
Total comprehensive income attributable to:				
Owners of the Company		253	356	(28.9)
<u>Other information</u>				
Adjusted EBITDA		4,369	3,989	9.5

Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortisation; and excludes unrealised foreign exchange by adding back unrealised foreign exchange loss and deducting unrealised foreign exchange gain.

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

B. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

31 January 2025

	Note	Group		Company	
		31 January 2025 S\$'000	31 July 2024 S\$'000	31 January 2025 S\$'000	31 July 2024 S\$'000
ASSETS					
Current assets:					
Cash and cash equivalents		6,886	4,974	80	93
Trade receivables		27,242	25,392	-	-
Other receivables		4,116	3,539	5,056	5,019
Contract assets		12,433	14,986	-	-
Income tax receivable		400	406	-	-
Inventories		18,262	18,072	-	-
Total current assets		<u>69,339</u>	<u>67,369</u>	<u>5,136</u>	<u>5,112</u>
Non-current assets:					
Other receivables		343	149	20,787	21,021
Property, plant and equipment	11	49,573	47,355	-	-
Right-of-use assets	10	12,543	13,221	-	-
Joint venture		1,736	1,736	-	-
Intangible assets		1,661	1,662	-	-
Deferred tax assets		41	-	-	-
Subsidiaries		-	-	50,755	50,739
Total non-current assets		<u>65,897</u>	<u>64,123</u>	<u>71,542</u>	<u>71,760</u>
Total assets		<u>135,236</u>	<u>131,492</u>	<u>76,678</u>	<u>76,872</u>
LIABILITIES AND EQUITY					
Current liabilities:					
Bank borrowings	12	25,233	18,206	-	-
Contract liabilities		858	358	-	-
Trade payables		10,450	12,445	-	-
Other payables		7,398	8,469	923	1,247
Lease liabilities	13	1,479	1,706	-	-
Income tax payable		380	135	-	-
Total current liabilities		<u>45,798</u>	<u>41,319</u>	<u>923</u>	<u>1,247</u>
Non-current liabilities:					
Bank borrowings	12	262	782	-	-
Other payables		210	214	-	-
Lease liabilities	13	11,458	11,774	-	-
Deferred tax liabilities		2,673	2,837	-	-
Total non-current liabilities		<u>14,603</u>	<u>15,607</u>	<u>-</u>	<u>-</u>
Capital and reserves:					
Share capital	14	51,034	51,034	51,034	51,034
Treasury shares		(37)	(37)	(37)	(37)
Share option reserve		2,379	2,355	2,379	2,355
Currency translation reserve		(2,830)	(2,838)	-	-
Capital reserve		(169)	(169)	-	-
Statutory reserve		917	710	-	-
Revaluation reserve		2,965	2,965	-	-
Retained earnings		20,576	20,546	22,379	22,273
Total equity		<u>74,835</u>	<u>74,566</u>	<u>75,755</u>	<u>75,625</u>
Total liabilities and equity		<u>135,236</u>	<u>131,492</u>	<u>76,678</u>	<u>76,872</u>

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

C. CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

31 January 2025

	Share capital	Treasury shares	Share option reserve	Currency translation reserve	Capital reserve	Statutory reserve	Revaluation reserve	Retained earnings	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
FY 2025									
Group									
Balance at 1 August 2024	51,034	(37)	2,355	(2,838)	(169)	710	2,965	20,546	74,566
Total comprehensive income for the period:									
Profit for the period	-	-	-	-	-	-	-	245	245
Other comprehensive income for the period	-	-	-	8	-	(8)	-	-	-
Total	-	-	-	8	-	(8)	-	245	245
Transactions with owners, recognised directly in equity:									
Dividends	-	-	-	-	-	-	-	-	-
Recognition of share-based payment	-	-	24	-	-	-	-	-	24
Transfer to statutory reserve	-	-	-	-	-	215	-	(215)	-
Total	-	-	24	-	-	215	-	(215)	24
Balance at 31 January 2025	51,034	(37)	2,379	(2,830)	(169)	917	2,965	20,576	74,835
FY 2024									
Group									
Balance at 1 August 2023	51,034	(37)	2,232	(2,396)	(169)	705	2,965	24,224	78,558
Total comprehensive income for the period:									
Profit for the period	-	-	-	-	-	-	-	224	224
Other comprehensive loss for the period	-	-	-	132	-	9	-	-	141
Total	-	-	-	132	-	9	-	224	365
Transactions with owners, recognised directly in equity:									
Dividends	-	-	-	-	-	-	-	(2,300)	(2,300)
Recognition of share-based payment	-	-	61	-	-	-	-	-	61
Transfer to statutory reserve	-	-	-	-	-	16	-	(16)	-
Total	-	-	61	-	-	16	-	(2,316)	(2,239)
Balance at 31 January 2024	51,034	(37)	2,293	(2,264)	(169)	730	2,965	22,132	76,684

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

C. CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

31 January 2025

	Share capital	Treasury shares	Share option reserve	Retained earnings	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
FY 2025					
Company					
Balance at 1 August 2024	51,034	(37)	2,355	22,273	75,625
Total comprehensive income for the period:					
Profit for the period	-	-	-	106	106
Transactions with owners, recognised directly in equity:					
Dividends	-	-	-	-	-
Recognition of share-based payment	-	-	24	-	24
Total	-	-	24	-	24
Balance at 31 January 2025	51,034	(37)	2,379	22,379	75,755
FY 2024					
Company					
Balance at 1 August 2023	51,034	(37)	2,232	23,909	77,138
Total comprehensive income for the period:					
Profit for the period	-	-	-	128	128
Transactions with owners, recognised directly in equity:					
Dividends	-	-	-	(2,300)	(2,300)
Recognition of share-based payment	-	-	61	-	61
Total	-	-	61	(2,300)	(2,239)
Balance at 31 January 2024	51,034	(37)	2,293	21,737	75,027

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

D. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

31 January 2025

	Group	
	6 months ended 31 January 2025	6 months ended 31 January 2024
	S\$'000	S\$'000
Operating activities:		
Profit before income tax	505	277
Adjustments for:		
Reversal of allowance for inventory obsolescence	-	(37)
Amortisation of intangible assets	50	36
Depreciation of property, plant and equipment	2,671	2,706
Depreciation of right-of-use assets	764	678
Gain on disposal of property, plant and equipment	(41)	(6)
Interest expense	667	412
Write off of property, plant and equipment	5	-
Share-based payment expenses	24	61
Foreign exchange gain	(85)	(182)
Operating cash flows before movements in working capital	4,560	3,945
Trade receivables	(1,757)	(1,992)
Other receivables	(675)	(614)
Inventories	(338)	3,601
Contract assets	2,553	(2,334)
Trade payables	(1,931)	(581)
Other payables	(1,258)	(2,737)
Contract liabilities	500	(25)
Cash generated from (used in) operations	1,654	(737)
Interest paid	(546)	(207)
Income taxes paid	(171)	(243)
Net cash from (used in) operating activities	937	(1,187)
Investing activities:		
Purchase of property, plant and equipment (see (a))	(4,140)	(5,691)
Deposit for purchase of property, plant and equipment	(79)	-
Proceeds on disposal of property, plant and equipment	44	57
Addition to intangible assets	(50)	(92)
Net cash used in investing activities	(4,225)	(5,726)

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

D. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
31 January 2025

	Group	
	6 months ended 31 January 2025	6 months ended 31 January 2024
	S\$'000	S\$'000
Financing activities:		
Proceeds from bank borrowings	7,031	7,012
Repayment of bank borrowings	(542)	(1,116)
Repayment of lease liabilities	(1,313)	(791)
Dividends paid	-	(2,300)
Net cash from financing activities	5,176	2,805
Net increase (decrease) in cash and cash equivalents	1,888	(4,108)
Cash and cash equivalents at beginning of period	4,974	8,566
Effect of foreign exchange rate changes	24	2
Cash and cash equivalents at end of period	6,886	4,460
Analysis of the balances of cash and cash equivalents:		
Cash and bank balances	6,886	4,460

Note (a):

During the period, the Group acquired property, plant and equipment with an aggregate cost of S\$4,307,000 (31 January 2024: S\$5,670,000) of which S\$434,000 (31 January 2024: S\$359,000) remain unpaid at the end of the period. Cash payments of S\$4,140,000 (31 January 2024: S\$5,691,000) were made to purchase property, plant and equipment of which S\$267,000 (31 January 2024: S\$380,000) pertains to payment of prior period outstanding balance.

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1 Corporate information

The Company is incorporated and domiciled in Singapore whose shares are publicly traded on the Mainboard of the Singapore Exchange. These condensed interim consolidated financial statements as at and for the six month ended 31 January 2025 comprise the Company and its subsidiaries (collectively, the Group).

The principal activity of the Company is that of investment holding.

The principal activities of the Group are:

- a) Sale, developing, manufacturing and assembly of medical devices;
- b) Project design and engineering services; and
- c) Manufacturing, trading and distributing of pipes and pipe fittings

2 Basis of Preparation

The condensed interim financial statements for the six months ended 31 January 2025 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 July 2024.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company's functional currency.

2.1 New and amended standards adopted by the Group

The Group has applied the same accounting policies and methods of computations for the current reporting period consistent with those of the most recent audited financial statement except for the adoption of new and revised accounting standards (including its consequential amendments) and interpretations applicable for the financial period beginning 1 August 2024.

The adoption of these new/revised accounting standards (including its consequential amendments) and interpretations does not result in changes to the Group's and Company's accounting policies and has no material effect on the half year announcement.

2.2 Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgement, estimates and assumptions that affect the actual application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 July 2024.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

2.2 Use of judgements and estimates (cont'd)

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

- (i) Impairment test of property, plant and equipment and goodwill used in Medical devices segment: key assumption underlying recoverable amounts
- (ii) Calculation of expected credit loss: forward looking information that is based on assumptions for the future movement of different economic drivers and how these drivers will affect each others
- (iii) Allowances for inventories: write down of inventories to net realisable value and costing of inventories to be based on normal production capacity and unallocated fixed overheads should be expensed off
- (iv) Income tax: subject to numerous tax jurisdictions where judgement is involved in determining the Group-wide provision for income taxes
- (v) Impairment of investments in subsidiaries: reviews the investments in the subsidiaries periodically with the view of assessing whether there is any indication of impairment.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

4 Segment information

For management purposes, the Group is currently organised into two main business activities. The business activities are the basis on which the Group reports to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

The two main business activities are as follows:

- (a) Medical devices segment - Manufacturing and developing medical devices.
- (b) Pipes and pipe fittings segment - Manufacturing, trading and distributing of pipes and pipe fittings.

Segmented revenue and results for business or geographical segments of the Group in the form presented in the issuer's most recent audited annual financial statements, with comparative information for the immediately preceding period.

4.1 Reportable segments

	Medical devices		Pipes & pipe fittings		Eliminations		Total	
	6 months ended 31 January 2025	6 months ended 31 January 2024	6 months ended 31 January 2025	6 months ended 31 January 2024	6 months ended 31 January 2025	6 months ended 31 January 2024	6 months ended 31 January 2025	6 months ended 31 January 2024
	S\$'000							
Revenue								
External sales	35,021	31,690	19,288	19,367	-	-	54,309	51,057
Results								
Segment result	(366)	(1,617)	3,555	4,097	(667)	(445)	2,522	2,035
Unallocated expenses							(1,350)	(1,346)
Interest expense	(489)	(311)	(184)	(112)	6	11	(667)	(412)
Profit before income tax							505	277
Income tax expense							(260)	(53)
Profit for the period							245	224
Other information								
Capital expenditure	3,436	4,954	871	716	-	-	4,307	5,670
Depreciation and amortisation	2,418	2,512	1,067	908	-	-	3,485	3,420
Balance Sheet								
Assets								
Segment assets	97,789	89,888	37,310	36,471	-	-	135,099	126,359
Unallocated corporate assets							137	287
Consolidated total assets							135,236	126,646
Liabilities								
Segment liabilities	43,625	32,074	15,853	16,786	-	-	59,478	48,860
Unallocated corporate liabilities							923	1,102
Consolidated total liabilities							60,401	49,962

Geographical segments

Revenue is analysed by the location of incorporation of the billing entity. Segment assets and capital expenditure are analysed by the geographical area in which the assets are located.

	Revenue		Segment Assets		Capital Expenditure	
	6 months ended 31 January 2025	6 months ended 31 January 2024	6 months ended 31 January 2025	6 months ended 31 January 2024	6 months ended 31 January 2025	6 months ended 31 January 2024
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Singapore	46,370	45,646	56,884	69,549	1,077	4,711
Malaysia	3,140	2,004	6,645	5,681	32	167
China	3,124	789	42,663	47,678	106	738
United Kingdom	1,675	2,618	2,968	3,736	121	54
Mexico	-	-	26,076	2	2,971	-
	54,309	51,057	135,236	126,646	4,307	5,670

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

4 Segment information (cont'd)

4.2 Disaggregation of revenue

	6 months ended 31 January 2025 S\$'000	6 months ended 31 January 2024 S\$'000
<u>Segment revenue - Sales of goods</u>		
Medical devices segment	35,021	31,690
Pipes and pipe fittings segment	19,288	19,367
	<u>54,309</u>	<u>51,057</u>
<u>Timing of revenue recognition</u>		
At a point in time:		
Medical devices segment	1,192	6,513
Pipes and pipe fittings segment	19,288	19,367
	<u>20,480</u>	<u>25,880</u>
Over time:		
Medical devices segment	33,829	25,177
	<u>54,309</u>	<u>51,057</u>

5 Profit for the period

Profit for the period has been arrived at after crediting/(charging):

	6 months ended 31 January 2025 S\$'000	6 months ended 31 January 2024 S\$'000
Income from tooling, mould and maintenance services	1,370	1,326
Foreign exchange		
- realised foreign exchange gain, net	201	896
- unrealised foreign exchange gain, net	288	120
Government grant	36	26
Selling and marketing expenses	(390)	(263)
Reversal of allowance for inventory obsolescence	-	37
Factory consumables	(242)	(247)
Laboratory and testing	(167)	(138)
Professional fees	(355)	(504)
Repair and maintenance	(679)	(535)
Sterilisation and decontamination	(39)	(21)
Tooling expenses	(499)	(206)
Transportation and freight	(587)	(472)
Travelling and entertainment	(270)	(234)
Water and electricity	(1,827)	(1,711)

6 Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	6 months ended 31 January 2025 S\$'000	6 months ended 31 January 2024 S\$'000
Current tax	(418)	(177)
Adjustment in respect of prior period	(20)	-
Deferred tax expense relating to the origination and reversal of temporary difference	201	148
Withholding tax *	(23)	(24)
Total	<u>(260)</u>	<u>(53)</u>

* Withholding tax arises from interests and rental charges to subsidiaries.

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

7 Financial Assets and Financial Liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 January 2025 and 31 July 2024:

	Group		Company	
	31 January 2025 S\$'000	31 July 2024 S\$'000	31 January 2025 S\$'000	31 July 2024 S\$'000
Financial assets				
Loans and receivables (including cash and cash equivalents), at amortised cost:				
- Cash and cash equivalents	6,886	4,974	80	93
- Trade receivables	27,242	25,392	-	-
- Other receivables (excluding prepayments and VAT input)	2,308	1,687	25,843	26,021
At amortised cost	<u>36,436</u>	<u>32,053</u>	<u>25,923</u>	<u>26,114</u>
Financial liabilities				
Amortised cost:				
- Bank borrowings	25,495	18,988	-	-
- Trade payables	10,450	12,445	-	-
- Other payables	7,608	8,184	923	1,257
At amortised cost	<u>43,553</u>	<u>39,617</u>	<u>923</u>	<u>1,257</u>
Lease liabilities	<u>12,937</u>	<u>13,480</u>	-	-

8 Holding company and related party transactions

The Company is a subsidiary of Venner Capital S.A., incorporated in the Republic of Panama, which is also its ultimate holding company. Venner Capital S.A. was previously owned by the Bird Island Trust ("BIT"), a fully discretionary trust under Liechtenstein law, the trustee of which was CTX Treuhand AG, a trust company based in Liechtenstein (the "Trustee"). On 28 February 2025, the Trustee exercised a power of appointment to transfer the entire trust fund of the BIT to Mrs. Jane Rose Philomene Gaines-Cooper, one of the discretionary beneficiaries of the BIT. Once the entire trust fund was appointed, the BIT's discretionary and active management duties ended. The legal title to the individual assets comprising the trust fund, including Venner Capital S.A., are in the process of being transferred to Mrs. Jane Rose Philomene Gaines-Cooper. Until those transfers occur, the Trustee holds the legal title to those assets as nominee for Mrs. Jane Rose Philomene Gaines-Cooper who has an absolute and immediate right to them, with no further discretion or conditions. Accordingly, the interests in Venner Capital S.A. belong to Mrs. Jane Rose Philomene Gaines-Cooper.

Some of the Company's transactions and arrangements are with the subsidiaries in the Group and of the ultimate holding company and the effect of these on the basis determined between the parties is reflected in these financial statements. The intercompany balances are unsecured, interest-free and repayable on demand unless otherwise stated.

Transactions between the Company and its subsidiaries have been eliminated on consolidation and are therefore not disclosed in this note.

During the period, Group entities entered into the following transactions with group companies of the ultimate holding company:

	Group	
	31 January 2025 S\$'000	31 January 2024 S\$'000
Sale of goods	638	375
Rental income	23	20
Miscellaneous income	41	57
	<u>702</u>	<u>452</u>

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S\$100,000 and transactions under shareholders' mandate pursuant to Rule 920) S\$'000	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000) S\$'000
Subsidiaries and associates of Venner Capital S.A.	Venner Capital S.A. is a controlling shareholder of the Company	-	638

9 Related party transaction

Some of the Group's transactions and arrangements are with related parties and the effect of these on the basis determined between the parties is reflected in these financial statements. The balances are unsecured, interest-free and repayable on demand unless otherwise stated.

During the period, the Group entities entered into the following transactions with related parties as follows:

	Group	
	31 January 2025 S\$'000	31 January 2024 S\$'000
Entity in which a director is a partner		
Legal fees expense	(40)	(55)

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

10 Right-of-use assets

	Land	Factory space	Motor vehicle	Total
	S\$'000	S\$'000	S\$	S\$'000
Cost:				
At 1 August 2024	3,568	12,812	310	16,690
Addition	-	-	383	383
Reclassification to property, plant and equipment	-	(221)	(161)	(382)
Currency re-alignment	-	54	-	54
At 31 January 2025	<u>3,568</u>	<u>12,645</u>	<u>532</u>	<u>16,745</u>
Accumulated depreciation:				
At 1 August 2024	507	2,919	43	3,469
Depreciation for the period	52	700	12	764
Reclassification to property, plant and equipment	-	-	(32)	(32)
Currency re-alignment	-	1	-	1
At 31 January 2025	<u>559</u>	<u>3,620</u>	<u>23</u>	<u>4,202</u>
Carrying amount:				
At 31 January 2025	<u>3,009</u>	<u>9,025</u>	<u>509</u>	<u>12,543</u>
At 31 July 2024	<u>3,061</u>	<u>9,893</u>	<u>267</u>	<u>13,221</u>

11 Property, plant and equipment

During the six months ended 31 January 2025, the Group acquired assets amounting to S\$4,307,000 (31 January 2024: S\$5,670,000).

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

12 Bank borrowings

Amount repayable in one year or less, or on demand

As at 31 January 2025		As at 31 July 2024	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
25,233	-	18,206	-

Amount repayable after one year

As at 31 January 2025		As at 31 July 2024	
Secured S\$'000	Unsecured S\$'000	Secured S\$'000	Unsecured S\$'000
262	-	782	-

Details of any collateral

The Group's bank borrowings are secured by way of legal mortgages over its leasehold land property of carrying value of approximately S\$8,422,000 (31 July 2024: S\$8,671,000) and corporate guarantee by the Company of S\$26,985,000 and US\$2,000,000 (31 July 2024: S\$26,985,000 and US\$2,000,000).

13 Lease liabilities

Amount repayable in one year or less, or on demand

Amount repayable after one year

As at 31 January 2025 S\$'000	As at 31 July 2024 S\$'000
1,479	1,706
11,458	11,774

14 Share capital

14.1 Details of any changes in the Company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as well as the number of shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Changes in share capital

	Number of shares			
	As at 31 January 2025		As at 31 January 2024	
	Number of shares	S\$'000	Number of shares	S\$'000
Balance at the beginning of the financial period	511,537,699	51,034	511,537,699	51,034
Issue of shares pursuant to the exercise of share options	-	-	-	-
Balance at the end of the financial period	511,537,699	51,034	511,537,699	51,034

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

14 Share capital (cont'd)

14.1 Outstanding share options

Grant date	Exercise price per share	Number of share options						Exercise period	
		As at 31 January 2024	Issued	Exercised	As at 31 July 2024	Issued	Forfeited		As at 31 January 2025
18 January 2016	S\$ 0.115	9,490,000	-	-	9,490,000	-	-	9,490,000	19 January 2017 to 18 January 2026
23 January 2017	0.108	7,900,000	-	-	7,900,000	-	-	7,900,000	24 January 2018 to 23 January 2027
11 January 2022	0.227	5,600,000	-	-	5,600,000	-	(1,650,000)	3,950,000	12 January 2023 to 11 January 2032
		22,990,000		-	22,990,000	-	(1,650,000)	21,340,000	

14.2 To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

The total number of issued shares excluding treasury shares:

	As at 31 January 2025	As at 31 July 2024
Number of issued shares	511,537,699	511,537,699
Treasury shares	461,000	461,000
Number of issued shares excluding treasury	511,076,699	511,076,699

14.3 A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

	As at 31 January 2025		As at 31 July 2024	
	Number of shares	S\$'000	Number of shares	S\$'000
Balance at the beginning of the financial period	461,000	37	461,000	37
Balance at the end of the financial period	461,000	37	461,000	37

There were no sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

15 Dividends

(a) Current financial period reported on

Any dividend recommend for the current financial period reported on?

No dividend was declared or recommended for the current period reported on.

In order to provide greater flexibility for managing the Group's capital needs throughout the year, dividend will be determined and declared at year end rather than half yearly. This flexibility will also place the Group in a stronger position to manage uncertainties in the macro environment as well as the Group's working capital, cashflow and capital expenditure requirements.

(b) Corresponding period of the immediately preceding financial year

Any dividend declared for the corresponding period of the immediately preceding financial period?

No dividend was declared or recommended for the corresponding period of the immediately preceding financial period.

(c) Date payable

Not applicable

(d) Books closure date

Not applicable

If no dividend has been declared/recommended, a statement to that effect.

Please refer to paragraph 15(a).

VICPLAS INTERNATIONAL LTD AND ITS SUBSIDIARIES

E. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

16 Net asset value

Net asset value for the issuer and Group per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the current financial period reported on and the immediately preceding financial year.

Group

Net asset value per ordinary share

31 January 2025 (in cents)	31 July 2024 (in cents)
14.64	14.59

Company

Net asset value per ordinary share

31 January 2025 (in cents)	31 July 2024 (in cents)
14.82	14.80

The calculation of net asset value per ordinary share is based on 511,076,699 ordinary shares in issue excluding treasury shares as at 31 January 2025 (31 July 2024: 511,076,699 ordinary shares).

17 Earnings per share

Earnings per ordinary share of the Group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

Earnings per ordinary share for the period based on the profit after tax attributable to shareholders

(a) Based on weighted average number of ordinary shares in issue
- Weighted average number of shares

(b) On a fully diluted basis

- Adjusted weighted average number of shares

31 January 2025 (in cents)	31 January 2024 (in cents)
0.05	0.04
511,076,699	511,076,699
0.05	0.04
511,076,966	513,708,552

Other Information Required by Listing Rule Appendix 7.2

Other information

1 Review

The condensed consolidated statement of financial position of Vicplas International Ltd and its subsidiaries as at 31 January 2025 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

2 A review of the performance of the Group to the extent necessary for a reasonable understanding of the Group's business. It must include a discussion of the following: -

(a) Any significant factors that affected the turnover, costs and earnings of the Group for the current period reported on, including (where applicable) seasonal or cyclical factors; and

(b) Any material factors that affected the cash flow, working capital, assets or liabilities of the Group during the current period reported on.

Income statement

Revenue for the Company and its subsidiaries (the "Group") increased to S\$54.3 million for the six months ended 31 January 2025 ("1H FY2025") from S\$51.1 million for the six months ended 31 January 2024 ("1H FY2024") due to higher revenue from medical devices segment.

The revenue for medical devices segment was S\$35.0 million in 1H FY2025, an increase of 10.5% from 1H FY2024 due to an increase in orders from certain customers and the gradual recovery of their post pandemic inventory levels. The revenue for the pipes and pipe fittings segment was S\$19.3 million in 1H FY2025, a slight decline of 0.4% from 1H FY2024. This decrease was attributed to the segment's prudent approach in balancing sales against increasing credit risk exposure.

Other income decreased by 14.1% in 1H FY2025 mainly due to lower foreign exchange gain of S\$0.5 million in 1H FY2025 as compared to S\$1.0 million in 1H FY2024.

Raw materials and consumables used increased by 3.7% mainly due to higher production activities in the medical devices segment.

Employee benefits expense (including salary) increased by 2.6% due to increased headcount and overtime.

Other operating expenses increased by 16.6% mainly due to higher production activities (including the start of production activities in the new Mexico plant) that resulted in higher selling and marketing, water and electricity, transportation and freight, repair and maintenance, and tooling expenses.

Income tax expense increased to S\$0.3 million in 1H FY2025 from S\$0.1 million in 1H FY2024 due to accruals made for income tax for the new Mexico plant.

Overall, the Group recorded profit before tax of S\$0.5 million for 1H FY2025, an increase of 82.3% from S\$0.3 million for 1H FY2024; and profit after tax of S\$245,000 for 1H FY2025, an increase of 9.4% as compared to S\$224,000 for 1H FY2024. The Group's adjusted EBITDA for 1H FY2025 was S\$4.4 million, an increase of 9.5% as compared to S\$4.0 million for 1H FY2024.

(Note: Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortisation; and excludes unrealised foreign exchange by adding back unrealised foreign exchange loss and deducting unrealised foreign exchange gain.)

Statement of financial position

Trade receivables increased mainly due to the increase in revenue in the medical devices segment.

Contract assets decreased due to lesser devices in production and post-production in the medical devices segment for contracts whereby the revenue has been recognised over time as at 31 January 2025 as compared to 31 July 2024. This was mainly due to the one week shut down in production during the Lunar New Year period in January 2025.

Property, plant and equipment increased mainly due to capital expenditure in the new Mexico plant.

Right-of-use assets and Lease liabilities (total of current and non-current) decreased mainly due to depreciation of existing facilities and its corresponding amortisation of rental contracts for the existing facilities.

Total Bank borrowings (by aggregating current and non-current) increased to fund increased working capital and capital expenditure requirements.

Other payables decreased mainly due to payment of accruals, such as bonuses.

Other information (cont'd)

Cash flow

Net cash from operating activities for 1H FY2025 was S\$0.9 million as compared to net cash used in operating activities of S\$1.2 million for 1H FY2024 mainly due to higher profit before income tax and improvement in working capital.

Net cash used in investing activities was S\$4.2 million in 1H FY2025 which was lower as compared to S\$5.7 million in 1H FY2024 mainly due to lower capital expenditure incurred in 1H FY2025 as lower amounts were required for the new Mexico plant.

Net cash from financing activities was S\$5.2 million in 1H FY2025 as compared to S\$2.8 million in 1H FY2024 mainly due to the absence of dividend payout in 1H FY2025.

3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

There was no forecast or prospect statement disclosed to shareholders previously.

4 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months.

Medical devices segment

The medical devices segment recorded revenue of S\$35.0 million in 1H FY2025, an increase of 10.5% from 1H FY2024 due mainly to an increase in orders following adjustments made over the course of the last two financial years by certain customers in their post-pandemic inventory holdings. This was a pleasing improvement notwithstanding that Lunar New Year was in late January this year which caused the segment losing one week of production in its China plants. The segment faced increased operating costs in 1H FY2025, associated with the Changzhou plant extension, new business development costs and startup related costs of the new plant in Juarez, Mexico. The Mexico plant is expected to contribute to segmental revenue in the second half of the financial year ending 31 July 2025. The segment has been successful in attracting new projects for the Mexico plant and these projects will be commercialised in the quarters ahead. Due to the improved revenue but higher base expenses as explained above, the segment recorded an improved negative result of S\$0.4 million for 1H FY2025 (as compared to a negative result of S\$1.6 million for 1H FY2024).

During 1H FY2025, the segment continued to focus on building up new capabilities, closing future project opportunities, as well as validating its new Mexico plant to improve its flexibility and offerings to its global customer base. The "In China for China" business is also gaining momentum.

The current expectation is for the revenue of the medical devices segment to improve as new projects are commercialised and as the Mexico plant begins to contribute to segmental revenue. However, the segmental results of the medical devices segment will continue to be constrained in the short term as the Mexico plant begins its operations and its utilisation ramps up gradually to absorb its operating and amortisation costs. There are also continuing operating costs associated with the Changzhou plant extension whilst its utilisation improves in the segment's "In China for China" business. After this phase is completed, the segment will be well-positioned to offer greater manufacturing flexibility and further grow its global customer base in key medical devices markets such as USA, Europe and Japan as well as expand its capability to service new projects for the China market. The segment continues to prioritise commercialising its funnel of new projects in order to meet its customers' market launch dates.

Pipes and pipe fittings segment

The pipes and pipe fittings segment recorded revenue of S\$19.3 million in 1H FY2025, compared to S\$19.4 million in 1H FY2024. While the segment benefited from the robust activity in Singapore's built environment, particularly in housing and civil engineering projects, it also faced intensified competition and heightened credit exposure risks. To mitigate these challenges, the segment focused on a prudent sales approach with an emphasis on credit risk management.

The segment continues to broaden its presence in civil engineering projects while further solidifying its leadership in residential projects, particularly in the public housing sector. By leveraging on the four Green Marks awarded by the Singapore Green Building Council, the segment not only aligns with industry sustainability trends but also upholds high-quality standards. Moreover, the segment's local manufacturing presence provides supply chain resilience and enables seamless delivery to meet the rapid pace of construction demands. While demand from the built environment is expected to remain strong, it will continue to focus on managing competition, cost pressures and credit risks.

(Note: The segmental results of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 4 of the Condensed Interim Financial Statements.)

Group

The Group recorded a revenue of S\$54.3 million in 1H FY2025 which was an increase of 6.4% over the revenue of S\$51.1 million in 1H FY2024, and a profit after tax of S\$245,000 in 1H FY2025 as compared to S\$224,000 in 1H FY2024 due to the improved (albeit negative) results of the medical devices segment and slightly lower positive results of the pipes and pipe fittings segment.

The current expectation is for the Group's revenue growth to be positive in the next reporting period largely in relation to the gradual recovery in the medical devices segment. The Group continues to face a challenging operating environment with an increasing fixed cost base for the medical devices segment as it incurs higher development, expansion and amortisation costs associated with its expanding global footprint to meet customer demand.

While the Group remains cautiously optimistic, it is keeping a vigilant watch on current challenges and uncertainties in the global macro and trading environment and the ongoing inflationary, interest rate and other cost pressures. The Group will continue to exercise prudent cost management, while developing new business opportunities, and strengthening its base for future growth.

Administrative update:

Administratively, the Group has rationalised and streamlined its wholly-owned subsidiaries in the medical devices segment from a largely linear/flat structure to a group structure under Forefront Medical Technology (Pte) Ltd, as holding company, for administrative efficacy. This internal holding arrangement does not have any impact on the Group's consolidated financial position.

5 Negative confirmation on interim financial results under Rule 705(5) of the Listing Manual.

The Chairman of the Board and Chairman of the Audit Committee on behalf of the Board of Directors hereby confirm that, to the best of their knowledge, nothing has come to the attention which may render the unaudited consolidated half year financial results for the period ended 31 January 2025 to be false or misleading in any material respect.

6 Confirmation of Directors and Executive Officers' undertakings pursuant to Listing Rule 720(1).

The Company has procured undertakings from all of its Directors and relevant Executive Officers (in the format set out in Appendix 7.7 under Rule 720(1)) in compliance with Listing Rule 720(1).

BY ORDER OF THE BOARD

Walter Tarca
Group Chief Executive Officer

13 March 2025